| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 4.789 | 8.801 | 9.601 | 10.192 | 10.247 | 11.924 | 14.303 | 14.481 | 13.922 |
| Total Income - EUR | - | 4.789 | 8.801 | 9.601 | 10.192 | 10.257 | 11.924 | 14.303 | 14.751 | 14.018 |
| Total Expenses - EUR | - | 4.755 | 6.563 | 5.769 | 5.797 | 5.615 | 5.201 | 5.913 | 6.054 | 6.004 |
| Gross Profit/Loss - EUR | - | 34 | 2.238 | 3.832 | 4.395 | 4.642 | 6.723 | 8.390 | 8.696 | 8.014 |
| Net Profit/Loss - EUR | - | -110 | 1.964 | 3.544 | 4.089 | 4.343 | 6.365 | 7.982 | 7.513 | 6.842 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Studiomed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 70.687 | 65.031 | 59.347 | 53.904 | 48.670 | 43.472 | 39.475 | 35.012 | 30.720 |
| Current Assets | - | 560 | 6.990 | 385 | 411 | 282 | 944 | 683 | 8.260 | 7.236 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 54 | 0 | 0 |
| Receivables | - | 319 | 400 | 371 | 407 | 273 | 462 | 412 | 7.074 | 787 |
| Cash | - | 241 | 6.590 | 14 | 4 | 8 | 482 | 217 | 1.185 | 6.448 |
| Shareholders Funds | - | -65 | 1.900 | 5.408 | 9.393 | 13.558 | 19.622 | 27.665 | 35.095 | 37.418 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 71.312 | 70.121 | 54.347 | 44.923 | 35.394 | 24.794 | 12.494 | 8.177 | 538 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Studiomed Srl